European Society for Medical Oncology

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, European Society for Medical Oncology, Cervical cancer, ESMO, Congress, PFS, Hazard, HIV disease progression rates, Clinical trial, Network, Risk, European Society of Gynaecological Oncology, Progression-free survival, Patient, Death, CI, Pharmaceutical industry

Topline results from innovaTV 301 were disclosed earlier this year following a pre-specified interim analysis conducted through an independent data monitoring committee.

Key Points: 
  • Topline results from innovaTV 301 were disclosed earlier this year following a pre-specified interim analysis conducted through an independent data monitoring committee.
  • The additional results were presented during the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2023.
  • In innovaTV 301, treatment-related adverse events (TRAEs) occurring in patients with TIVDAK were generally low grade and manageable with supportive care or dose modifications.
  • “We are excited to share the additional results of the innovaTV 301 trial, which demonstrated benefit in prolonging survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy,” said Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab.

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Knowledge, Research, Cholangiocarcinoma, CTX, ESMO, Progression-free survival, CUP, Foundation Medicine, MD, Bladder cancer, Doctor of Philosophy, PET, Neoplasm, Abstract, Liquid, Booths, BTC, University, Roche, Safety, Cancer, European Society for Medical Oncology, Liquid biopsy, MD Anderson Cancer Center, Patient, Prognosis, DNA, Pharmaceutical industry, Medical imaging

Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.

Key Points: 
  • Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.
  • In patients with CUP, the tumor of origin is unknown, which has historically made targeted treatment challenging.
  • As a result, there has been little progress in improving the poor outcomes for these patients.
  • Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO23 and visit us in person at Booths 727 and 728.

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Health, Genetics, Health Technology, Oncology, Congress, PSNL, Research, NeXT, European Society for Medical Oncology, Neoplasm, ESMO, Abstract, III, Medical imaging, Pharmaceutical industry

Personalis, Inc .

Key Points: 
  • Personalis, Inc .
  • (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on October 21 in Madrid, Spain.
  • Late-breaking abstracts are typically reserved for high-quality, new research findings from randomized phase II or phase III trials with implications for clinical practice or understanding of disease processes.
  • Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.

Massive Bio and ONCOassist® Announce Strategic Partnership at ESMO 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ESMO, Moonshot, Physician, European Society for Medical Oncology, SBIR, CE, Research, Multimedia, Drug development, ISOC, Clinical trial, Partnership, National Cancer Institute, AI, M&A, Cancer, CMO, Patient, Nursing, Pharmaceutical industry, Medical device, Hospital

and ONCOassist ® have announced a strategic partnership at the European Society for Medical Oncology (ESMO) 2023 conference in Madrid.

Key Points: 
  • and ONCOassist ® have announced a strategic partnership at the European Society for Medical Oncology (ESMO) 2023 conference in Madrid.
  • View the full release here: https://www.businesswire.com/news/home/20231019250308/en/
    Massive Bio and ONCOassist Announce Strategic Partnership at ESMO 2023 (Graphic: Business Wire)
    Dr. Richard Bambury , Co-founder and CMO of ONCOassist®, stated, "With ONCOassist® being a trusted tool for a vast number of oncology professionals, this partnership with Massive Bio represents a pivotal moment in our ongoing commitment to elevate the standards of oncology care."
  • Selin Kurnaz , CEO and Co-Founder of Massive Bio, commented, "At Massive Bio, our focus has been on harnessing AI and concierge services to provide real-time clinical trial options for patients and their oncologists.
  • Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Health Technology, Clinical Trials, Other Health, Congress, European Society for Medical Oncology, Cancer, NSCLC, Safety, MAIA, Patient, NYSE, ESMO, Pharmaceutical industry

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that preliminary safety and efficacy data from its ongoing Phase 2 clinical trial, THIO-101, was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain, October 20-24, 2023.

Key Points: 
  • MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that preliminary safety and efficacy data from its ongoing Phase 2 clinical trial, THIO-101, was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain, October 20-24, 2023.
  • THIO-101 is evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC) in sequential combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo®).
  • The abstract is available online at the ESMO Congress website , and MAIA is scheduled for poster presentation on Monday, October 23.
  • Details of the presentation are as follows:

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

Retrieved on: 
Sunday, October 22, 2023
Research, General Health, Radiology, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Health, Other Science, Patient, ESMO, Progression-free survival, Pembrolizumab, Congress, PFS, European Society for Medical Oncology, Multimedia, Inc., Confidence interval, Brentuximab vedotin, Risk, Platinum, OS, Death, Abstract, Pharmaceutical industry

The combination improved overall survival (OS) and progression-free survival (PFS) with statistically significant and clinically meaningful results in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

Key Points: 
  • The combination improved overall survival (OS) and progression-free survival (PFS) with statistically significant and clinically meaningful results in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
  • View the full release here: https://www.businesswire.com/news/home/20231017754680/en/
    The EV-302 study met its dual primary endpoints of OS and PFS, compared to platinum and gemcitabine chemotherapy.
  • 55% reduction in the risk of cancer progression or death compared to treatment with chemotherapy (HR=0.45; 95% CI: (0.38-0.54); P
  • The EV-302 trial is part of an extensive program evaluating this combination in multiple stages of urothelial cancer and other solid tumors.

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Pharmaceutical, Health, Oncology, European Society for Medical Oncology, Cervical cancer, Genmab, ESMO, Congress, PFS, Hazard, HIV disease progression rates, Inc., Clinical trial, Network, Risk, European Society of Gynaecological Oncology, Progression-free survival, Patient, Death, Pharmaceutical industry

Data were presented during the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • Data were presented during the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2023.
  • The confirmed objective response rate (ORR) was also statistically significantly improved with TIVDAK (17.8%) compared with chemotherapy (5.2%); odds ratio: 4.0 [95% CI, 2.1-7.6], p
  • In innovaTV 301, treatment-related adverse events (TRAEs) occurring in patients with TIVDAK were generally low grade and manageable with supportive care and dose modifications.
  • “Recurrent or metastatic cervical cancer is a devastating disease,” said Roger Dansey, M.D., President of Research and Development and Chief Medical Officer at Seagen.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

Retrieved on: 
Monday, October 23, 2023
NHS foundation trust, The Royal Marsden NHS Foundation Trust, Real-time, Plasma, Genomics, NYSE, ESMO, Leukemia, Biomarker, Nucleic acid thermodynamics, Chromatin immunoprecipitation, Hereditary nonpolyposis colorectal cancer, Colorectal cancer, Chromatin, PCR, Research, Science, Neoplasm, FIT, Volition, Oncology, Blood, European Society for Medical Oncology, Liquid biopsy, Chemistry, Royal Marsden Hospital, Automation, Translational Genomics Research Institute, CTCF, DNA, Vaccine, Medical imaging, Coal, Cancer

Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Key Points: 
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
  • Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
  • Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
  • Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

Retrieved on: 
Monday, October 23, 2023
TKI, Bone marrow, PRS, NSCLC, Notifiable disease, Mini, Aes, ESMO, TP53, QW, Hepatitis, Congress, PFS, European Society for Medical Oncology, CHB, Pharmacokinetics, Disease, Oncology, ORR, Safety, Cancer, Apoptosis, Patient, Prognosis, Cohort, EGFR, Pharmaceutical industry

The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.

Key Points: 
  • The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.
  • Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "Currently, there are many challenges in the treatment of NSCLC.
  • At the ESMO 2023, we presented the latest clinical data that continued to suggest encouraging therapeutic potential of pelcitoclax combined with osimertinib in EGFR-TKI-naïve patients with TP53- and EGFR-mutant NSCLC.
  • In earlier studies, pelcitoclax combined with osimertinib demonstrated clinical potential for the treatment of patients with EGFR-mutant advanced NSCLC resistant to EGFR-TKIs.

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Retrieved on: 
Monday, October 23, 2023
Data analysis, Metastasis, AACR, Ovarian cancer, ESMO, Prevalence, Cell, CD8, Immunity, Recurrence, Neoplasm, Oncology, KZIA, European Society for Medical Oncology, Patient, VEGFR3, Hypoxia, Medical imaging, Vaccine, Kazia Pelka

SYDNEY, Oct. 23, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected clinical data from the company's ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the European Society of Medical Oncology Congress 2023 (ESMO 2023) on Saturday, 21 October 2023.

Key Points: 
  • SYDNEY, Oct. 23, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected clinical data from the company's ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the European Society of Medical Oncology Congress 2023 (ESMO 2023) on Saturday, 21 October 2023.
  • Professor Carlos A Gomez-Roca, (IUCT-Oncopole, Toulouse France) presented data from a correlation analysis of tumour biopsies from six (6) enrolled patients with high grade serous ovarian cancer (HGS-OC).
  • To date, twenty (20) patients with advanced solid tumors have been dosed in in the ongoing Phase 1 clinical trial, and the trial has advanced to dose escalation cohort 6.
  • "We look forward to completing dose escalation in stage 1 of the ongoing study and progressing to stage 2 of the Phase 1 Study ."